Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination (TraNsgripe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01761435
Recruitment Status : Completed
First Posted : January 4, 2013
Last Update Posted : May 1, 2015
Sponsor:
Collaborator:
Spanish Network for Research in Infectious Diseases
Information provided by (Responsible Party):
Andalusian Network for Design and Translation of Advanced Therapies ( Fundación Pública Andaluza Progreso y Salud )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Randomized, multicenter, open label trial to compare safety and efficacy of two doses stationary flu vaccination vs one doses in Solid Organ Transplant Recipients.

Condition or disease Intervention/treatment Phase
Infection in Solid Organ Transplant Recipients Biological: Influenza vaccine Phase 3

Detailed Description:

The purposes of this study are:

  1. Evaluate the efficacy and safety of a double dose of seasonal flu vaccine compared to a single dose.
  2. Determine the specific cellular immune response produced after the first and second vaccine doses of seasonal flu vaccine by in vitro stimulation of specific memory cells (A and B flu viruses).
  3. Evaluate the humoral immune response produced after one dose vs two doses of seasonal flu vaccine by the measure of serum antibody levels.
  4. Evaluate clinical efficacy of stationary flu vaccine in solid organ transplant recipients.
  5. Evaluate a long term cellular and humoral response(1 year) of seasonal flu vaccine.
  6. Characterize the genetic expression profile of immune response after the flu vaccine in solid organ transplant recipients by means of a genetic sub-study.
  7. Characterize the flu vaccine effect (one dose and two doses) through the antibody anti-HLA(human leukocyte antigen), and its influence on the rejection rate in solid organ transplant recipients, by means of immunologic sub-study.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 499 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Randomized, Comparative and Prospective Clinical Trial Evaluating Efficacy and Safety of a Dose of Seasonal Flu Vaccine Compared to Two Doses of Vaccine for Prevention of Influenza in Solid Organ Transplant Recipients
Study Start Date : October 2012
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Influenza vaccine, second administration after 5 weeks
Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first one.
 Biological: Influenza vaccine

Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :

A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.

B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.

The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline.
Active Comparator: Influenza vaccine
Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
 Biological: Influenza vaccine

Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :

A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.

B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.

The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Seroconversion rates [ Time Frame: At 5, 10, 15 weeks, and 12 months after the first vaccine dose ]
    Difference in seroconversion rates in both treatment groups at 5, 10, 15 weeks, and 12 months after the first vaccine dose (percent of patients with 4 x increase in the pre-vaccination titers).


Secondary Outcome Measures :
  1. Postvaccination antibody titers [ Time Frame: At 5, 10, 15 weeks, and 12 months after the first vaccine dose. ]
    Geometric average postvaccination antibody titers and rate of increase between pre-and post-vaccination geometric mean, post-vaccination seroprotection rate (or percentage of individuals with a titer 1 / 40 as measured by RIH).

  2. Safety. [ Time Frame: At 5, 10, 15 weeks, and 12 months after the first vaccine dose ]
    Occurrence of grade 3 or 4 toxicity, death, hospitalization, retransplantation, acute rejection and chronic rejection

  3. Efficacy [ Time Frame: At 5, 10, 15 weeks, and 12 months after the first vaccine dose ]
    Detection of clinical cases of influenza following immunization. Nasal swabs to confirm infection with influenza virus by RT-PCR (Reverse transcription polymerase chain reaction).

  4. Antibody anti-HLA [ Time Frame: At 5, 10, 15 weeks, and 12 months after the first vaccine dose ]
    Characterize the flu vaccine effect (one dose and two doses) through the antibody anti-HLA levels, ant its influence on the rejection rate in solid organ transplant recipients, by means of immunologic sub-study.

  5. Cellular response [ Time Frame: At 5, 10, 15 weeks, and 12 months after the first vaccine dose ]
    Determination of the T cells specific immune response measured by production of INFg, IL-2 and IL-4 in the cytoplasm of CD4+ and CD8 + (mononuclear cells) specific for influenza virus by direct immunofluorescence and flow cytometry analysis.

  6. Clinical complications [ Time Frame: At 5, 10, 15 weeks, and 12 months after the first vaccine dose ]
    Clinical severity (hospitalization, ICU admission, death, rejection). Time to clinical stability will be register.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Solid organ transplant recipient.
  2. 16 years or older.
  3. More than 30 days after transplantation.
  4. Negative pregnancy test for women of childbearing potential
  5. The patient must give informed consent

Exclusion Criteria:

  1. No written informed consent.
  2. Acute rejection within 15 days prior to vaccination.
  3. Pregnancy.
  4. Hypersensitivity to the active substance, any of the excipients and waste, for example: eggs, egg albumin, chicken proteins.
  5. History of a previous serious reaction to immunization (eg Guillain-Barré syndrome).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01761435


Locations
Layout table for location information
Spain
Hospital Universitario Masqués de Valdecilla
Santander, Bilbao, Spain
Hospital Clinic Provincial de Barcelona
Barcelona, Spain
Hospital Universitario de Bellvitge
Barcelona, Spain
Hospital Universitario de Cruces
Bilbao, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital General Gregorio Marañon
Madrid, Spain
Hospital Ramón y Cajal
Madrid, Spain
Hospital Universitario 12 Octubre
Madrid, Spain
Hospital Vall d'Hebron
Madrid, Spain
Hospital Universitario Virgen del Rocío
Sevilla, Spain, 41013
Hospital Regional Virgen de la Macarena
Sevilla, Spain
Hospital la Fe de Valencia
Valencia, Spain
Sponsors and Collaborators
Fundación Pública Andaluza Progreso y Salud
Spanish Network for Research in Infectious Diseases
Investigators
Layout table for investigator information
Principal Investigator: Julian De la Torre Cisneros, PhD COMPLEJO HOSPITALARIO REGIONAL REINA SOFÍA
Principal Investigator: Francisco López Medrano, PhD Hospital Universitario 12 de Octubre
Principal Investigator: Patricia Muñoz García, PhD HOSPITAL GENERAL GREGORIO MARAÑÓN
Principal Investigator: Jesús Fortun Abete, PhD Hospital Universitario Ramon y Cajal
Principal Investigator: Joán Gavaldà Santapau, PhD HOSPITALS VALL D'HEBRON
Principal Investigator: Jordi Carratalá Fernández, PhD Hospital Universitari de Bellvitge
Principal Investigator: Asunción Moreno Camacho, PhD Hospital Clinic i provincial de Barcelona
Principal Investigator: José Miguel Montejo Baranda, PhD HOSPITAL UNIVERSITARIO DE CRUCES
Principal Investigator: Marino Blanes Julia, PhD Hospital Universitario La Fe
Principal Investigator: Alejandro Suarez Benjumea, PhD COMPLEJO HOSPITALARIO REGIONAL VIRGEN MACARENA
Principal Investigator: Carmen Fariñas Álvarez, PhD Hospital Universitario Marqués de Valdecilla
Principal Investigator: Maria Elisa Cordero Matia, PhD HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Fundación Pública Andaluza Progreso y Salud
ClinicalTrials.gov Identifier: NCT01761435    
Other Study ID Numbers: TraNsgripe1-2
First Posted: January 4, 2013    Key Record Dates
Last Update Posted: May 1, 2015
Last Verified: April 2015
Keywords provided by Andalusian Network for Design and Translation of Advanced Therapies ( Fundación Pública Andaluza Progreso y Salud ):
Influenza
Solid Organ Transplant Recipients
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
 Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases